Can transcription factors cause cancer?
Transcription factors (TFs) are commonly deregulated in the pathogenesis of human cancer and are a major class of cancer cell dependencies.
Why is it difficult to target transcription factors?
As such, transcription factors could be considered prime targets for drug development. However, transcription factors have been historically difficult to target, owing in part to the fact that they typically exert their activity via protein-protein and/or protein-DNA interactions.
Can transcription factors be drug targets?
Nuclear hormone receptors have a DNA binding domain and a ligand binding domain (LBD), of which the latter binds to a small-molecule modulator (hormone) that alters its activity to regulate gene expression43,44,45.
How can transcription factors be reduced?
Dimeric transcription factors need to form homodimers or heterodimers in order to activate transcription and to bind DNA. Thus, they can be inhibited by small-molecule inhibitors of the protein–protein interactions mediating the subunit association.
Which transcription factors may act as oncogenes to cause cancer?
The AP-1 transcription factor. Fos and Jun dimerize to form AP-1, which activates transcription of a variety of growth factor-inducible genes. G protein-coupled receptors and G proteins also act as oncogenes in some human tumors (Figure 15.29).
Why is transcription a good target for drugs?
Because of their pivotal role in the regulation of multiple genes, they are potential targets for pharmacological intervention in the control of disease processes.
Why are transcription factors of interest in pharmaceutical development?
Like cell-surface receptors, gene-specific transcription factors are attractive drug targets because they have substantial structural diversity. When considering systemic administration of drugs, gene-specific transcription factors have the added advantage of substantial specificity in their mode of action.
What are the inhibitors of transcription?
The Transcriptional Inhibitors, Actinomycin D and α-Amanitin, Activate the HIV-1 Promoter and Favor Phosphorylation of the RNA Polymerase II C-terminal Domain* Actinomycin D and α-amanitin are commonly used to inhibit transcription.
Can a transcription factor inhibit transcription?
Although the majority of the transcription factors that were initially characterized had a stimulatory effect on gene expression, it is now clear that transcription factors that inhibit gene transcription are at least as important in regulating a wide variety of processes, including development.
Which gene is involved in cancer?
The most commonly mutated gene in all cancers is TP53, which produces a protein that suppresses the growth of tumors. In addition, germline mutations in this gene can cause Li-Fraumeni syndrome, a rare, inherited disorder that leads to a higher risk of developing certain cancers.
Is there a role for transcription factors in the pathogenesis of cancer?
Many more signalling proteins are affected in cancer than transcription factors, electing transcription factors as cogent targets.
What are the different types of transcription factors?
Three main groups of transcription factors are known to be important in human cancer. The first to be recognized were the steroid receptors — for example, oestrogen receptors in breast cancer and androgen receptors in prostate cancer.
How are latlatent transcription factors activated?
Latent transcription factors might be activated at the cell membrane by either tyrosine (STATs) or serine (SMADs) phosphorylation. They then bind to the transport proteins called importins and enter the nucleus to participate in regulated gene transcription.